Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With Relapsed/Refractory Small Cell Lung Cancer

NCT03392064 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03392064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03392064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With Relapsed/Refractory Small Cell Lung Cancer
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Suspended
Start date
September 10, 2018
Completion date
January 14, 2028
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer